With the arrival of AstraZeneca's (AZN -0.4%) new CEO, and the company heading towards a steep...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

With the arrival of AstraZeneca's (AZN -0.4%) new CEO, and the company heading towards a steep patent cliff, speculation is rising over the company's potential targeting of takeover candidates, with Forest Labs (FRX) being bounced around by Street analysts as the most tempting target. Leerink Swann says AZN has the cash, and FRX has one of the best pipeline hit rates around and is spending hard on R&D. Exane agrees, adding that the two company's have "more than a significant overlap in certain product areas.